Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy.

Ramautarsing RA, van der Lugt J, Gorowara M, Kerr SJ, Burger D, Ruxrungtham K, Phanuphak P, Chaithongwongwatthana S, Avihingsanon A, Phanuphak N.

AIDS. 2011 Jun 19;25(10):1299-303. doi: 10.1097/QAD.0b013e328347f7e9.

PMID:
21516029
2.

Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women.

Izurieta P, Kakuda TN, Feys C, Witek J.

HIV Med. 2011 Apr;12(4):257-8. doi: 10.1111/j.1468-1293.2010.00874.x. No abstract available.

3.

Atazanavir pharmacokinetics with and without tenofovir during pregnancy.

Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS; IMPAACT 1026s Study Team.

J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):412-9. doi: 10.1097/QAI.0b013e31820fd093.

4.

Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy.

Cressey TR, Jourdain G, Rawangban B, Varadisai S, Kongpanichkul R, Sabsanong P, Yuthavisuthi P, Chirayus S, Ngo-Giang-Huong N, Voramongkol N, Pattarakulwanich S, Lallemant M; PHPT-5 Team.

AIDS. 2010 Sep 10;24(14):2193-200. doi: 10.1097/QAD.0b013e32833ce57d.

5.

Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.

Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, Flaherty JP, Boffito M, Namakula R, Ryan M, Nakabiito C, Back DJ, Khoo S, Merry C, Scarsi KK.

J Acquir Immune Defic Syndr. 2010 Nov;55(3):345-50. doi: 10.1097/QAI.0b013e3181e9871b.

6.

Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts.

Ford N, Mofenson L, Kranzer K, Medu L, Frigati L, Mills EJ, Calmy A.

AIDS. 2010 Jun 19;24(10):1461-70. doi: 10.1097/QAD.0b013e32833a2a14. Review.

PMID:
20479637
7.

Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.

Chantarangsu S, Cressey TR, Mahasirimongkol S, Capparelli E, Tawon Y, Ngo-Giang-Huong N, Jourdain G, Lallemant M, Chantratita W.

J Antimicrob Chemother. 2009 Dec;64(6):1265-73. doi: 10.1093/jac/dkp351. Epub 2009 Oct 6.

8.

Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.

Capparelli EV, Aweeka F, Hitti J, Stek A, Hu C, Burchett SK, Best B, Smith E, Read JS, Watts H, Nachman S, Thorpe EM Jr, Spector SA, Jimenez E, Shearer WT, Foca M, Mirochnick M; PACTG 1026S Study Team; PACTG P1022 Study Team.

HIV Med. 2008 Apr;9(4):214-20. doi: 10.1111/j.1468-1293.2008.00553.x.

9.

Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update.

Cressey TR, Lallemant M.

Infect Genet Evol. 2007 Mar;7(2):333-42. Epub 2006 Oct 11. Review.

PMID:
17045554
10.

Reduced lopinavir exposure during pregnancy.

Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS.

AIDS. 2006 Oct 3;20(15):1931-9.

PMID:
16988514
11.

Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.

Tracy TS, Venkataramanan R, Glover DD, Caritis SN; National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units.

Am J Obstet Gynecol. 2005 Feb;192(2):633-9.

PMID:
15696014
12.

Pharmacokinetics of antiretrovirals in pregnant women.

Mirochnick M, Capparelli E.

Clin Pharmacokinet. 2004;43(15):1071-87. Review.

PMID:
15568888
13.

Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.

Holland DT, DiFrancesco R, Stone J, Hamzeh F, Connor JD, Morse GD; Adult and Pediatric AIDS Clinical Trials Group Pharmacology Laboratory Committees, Pediatric AIDS Clinical Trials Group.

Antimicrob Agents Chemother. 2004 Mar;48(3):824-31.

14.
15.

Periconceptional exposure to efavirenz and neural tube defects.

De Santis M, Carducci B, De Santis L, Cavaliere AF, Straface G.

Arch Intern Med. 2002 Feb 11;162(3):355. No abstract available.

PMID:
11822930
16.

Myelomeningocele in a child with intrauterine exposure to efavirenz.

Fundarò C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E.

AIDS. 2002 Jan 25;16(2):299-300. No abstract available. Erratum in: AIDS. 2002 Jul 5;16(10):1443..

PMID:
11807320
Items per page

Supplemental Content

Write to the Help Desk